On November 10, 2026, Guggenheim analyst Subbu Nambi maintained a "Buy" rating for Adaptive Biotechnologies (ADPT) while raising the price target from $32.00 to $34.00. This new price target indicates a projected increase of 6.25%.
The recent rating change by Guggenheim reflects a positive outlook on Adaptive Biotechnologies, particularly in light of its advancements in immune-driven medicine. The company's innovative approach in high-throughput sequencing of T-cell and B-cell receptors positions it well within the healthcare sector, specifically in medical diagnostics and research. With a market capitalization of approximately $4.9 billion, Adaptive Biotechnologies is focused on providing critical diagnostic solutions, including its FDA-cleared clonoSEQ assay for monitoring minimal residual disease in various cancers.
This rating is significant as it comes amidst a series of positive adjustments from other analysts, including Morgan Stanley and TD Cowen, who have also raised their price targets recently.
https://www.gurufocus.com/news/9188875/adpt-maintained-by-guggenheim-price-target-raised-to-3400
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.